XOMA · CIK 0000791908
What XOMA Royalty Corporation told the SEC could break it.
XOMA Royalty's disclosures reflect the structural dependence of a royalty aggregator on outcomes it doesn't control. Its income hinges on its royalty and milestone providers winning regulatory approval and commercializing their products — including their contract manufacturers meeting cGMP standards — all outside XOMA's hands. That model carries real impairment risk: Alora discontinued commercial sales of DSUVIA in November 2024, a program XOMA had bought an economic interest in, leaving it reliant on residual Department of Defense sales. And proposed U.S. tariffs of up to 100% on imported branded or patented pharmaceuticals, announced in September 2025, could hurt its providers' economics and in turn its royalty income.
3 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Other disclosures
- dependence on third-party royalty/milestone providers' product success and cGMP compliancehigh
As a royalty aggregator, XOMA's income depends on its royalty/milestone providers achieving regulatory approval and commercializing their products, including their CMOs meeting cGMP — risks entirely outside XOMA's control.
“Our potential milestone and royalty providers may rely on third party manufacturers and such contract manufacturers are required to produce clinical product candidates under cGMP to meet acceptable standards for use in clinical trials and for commercial sale, as applicable.”
SEC filing →As of 2026 - royalty-stream impairment risk (DSUVIA discontinued by Alora)medium
Acquired royalty streams can fail — Alora discontinued commercial sales of DSUVIA in November 2024 (a program XOMA bought an economic interest in), leaving XOMA reliant only on residual DoD sales for recovery.
“In November 2024, Alora discontinued commercial sales of DSUVIA. We remain eligible for payments from sales to the DoD.”
SEC filing →As of 2026
Regulatory & policy
- proposed U.S. tariffs of up to 100% on imported branded/patented pharmaceuticalsmedium
In September 2025 the U.S. announced plans for up to 100% tariffs on imported branded/patented pharmaceuticals; if applied to APIs or finished products of XOMA's royalty providers, it could harm their economics and XOMA's royalty income.
“in September 2025, the United States announced plans to impose up to 100% tariffs on imported branded or patented pharmaceuticals, subject to certain exceptions.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Takeda Pharmaceutical Company Limited
“Revenue from contracts with customers for the year ended December 31, 2025, primarily included a milestone payment of $5.0 million pursuant to our Rezolute License 77 Table of Contents Agreement, $4.1 million pursuant to the Takeda Collaboration Agreement, including $3.0 million from a milestone payment and $1.1 million in other revenue, and $1.3 million in other milestone payments.”
Cited →Day One Biopharmaceuticals, Inc.
“OJEMDA was launched in the second quarter of 2024, and we expect income from related royalties to increase in future periods based on projections reported by Day One.”
Cited →“regulatory milestone payment of $25.0 million payable to XOMA and additional clinical and regulatory milestone payments up to $25.0 million payable to ActiveSite.”
Cited →“Additionally, for each product candidate, we are entitled to receive milestone payments of up to $3.0 million upon Janssen's achievement of certain clinical development and regulatory approval milestones. Additional milestone payments may be due for product candidates which are the subject of multiple clinical trials. Upon commercialization, we are eligible to receive a 0.75% royalty on net sales of each product.”
Cited →“Revenue from contracts with customers for the year ended December 31, 2025, primarily included a milestone payment of $5.0 million pursuant to our Rezolute License 77 Table of Contents Agreement, $4.1 million pursuant to the Takeda Collaboration Agreement, including $3.0 million from a milestone payment and $1.1 million in other revenue, and $1.3 million in other milestone payments.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch